Gamma-aminobutyric acid: Difference between revisions
No edit summary |
No edit summary |
||
| Line 2: | Line 2: | ||
|authorTag={{Ammu}} | |authorTag={{Ammu}} | ||
|genericName=[[gamma.-aminobutyric acid]] | |genericName=[[gamma.-aminobutyric acid]] | ||
|aOrAn= | |aOrAn=an | ||
|drugClass=[[anxiolytic]] | |drugClass=[[anxiolytic]] | ||
|indicationType=treatment | |indicationType=treatment | ||
|indication=epilepsy | |indication=[[epilepsy]] | ||
|adverseReactions=[[hypersensitivity]] | |adverseReactions=[[hypersensitivity]] | ||
|blackBoxWarningTitle=<span style="color:#FF0000;">ConditionName: </span> | |blackBoxWarningTitle=<span style="color:#FF0000;">ConditionName: </span> | ||
| Line 15: | Line 15: | ||
<!--FDA-Labeled Indications and Dosage (Adult)--> | <!--FDA-Labeled Indications and Dosage (Adult)--> | ||
|fdaLIADAdult=Adults and children 5 to 10 drops orally, 1 time daily or as otherwise directed by a health care professional. If symptoms persist, consult your health care professional. Consult a physician for use in children under 12 years of age. | |fdaLIADAdult=* Adults and children 5 to 10 drops orally, 1 time daily or as otherwise directed by a health care professional. If symptoms persist, consult your health care professional. * Consult a physician for use in children under 12 years of age. | ||
|offLabelAdultGuideSupport= | |offLabelAdultGuideSupport=There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in adult patients. | ||
There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in adult patients. | |||
<!--Non–Guideline-Supported Use (Adult)--> | <!--Non–Guideline-Supported Use (Adult)--> | ||
|offLabelAdultNoGuideSupport= | |offLabelAdultNoGuideSupport=* [[Epilepsy]], [[tardive dyskinesia]], [[spasicity]] | ||
|fdaLIADPed= | |fdaLIADPed=There is limited information regarding <i>FDA-Labeled Use</i> of {{PAGENAME}} in pediatric patients. | ||
There is limited information regarding <i>FDA-Labeled Use</i> of {{PAGENAME}} in pediatric patients. | |||
<!--Off-Label Use and Dosage (Pediatric)--> | <!--Off-Label Use and Dosage (Pediatric)--> | ||
<!--Guideline-Supported Use (Pediatric)--> | <!--Guideline-Supported Use (Pediatric)--> | ||
|offLabelPedGuideSupport= | |offLabelPedGuideSupport=There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients. | ||
There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients. | |||
<!--Non–Guideline-Supported Use (Pediatric)--> | <!--Non–Guideline-Supported Use (Pediatric)--> | ||
|offLabelPedNoGuideSupport= | |offLabelPedNoGuideSupport=There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients. | ||
There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients. | |||
<!--Contraindications--> | <!--Contraindications--> | ||
|contraindications=* Hypersensitivity to GABA | |contraindications=* [[Hypersensitivity]] to [[GABA]] | ||
|warnings=* WARNINGS: If pregnant or breast-feeding, ask a health professional before use. | |warnings=* WARNINGS: If [[pregnant]] or [[breast-feeding]], ask a health professional before use. | ||
|clinicalTrials=There is limited information regarding <i>Clinical Trial Experience</i> of {{PAGENAME}} in the drug label. | |clinicalTrials=There is limited information regarding <i>Clinical Trial Experience</i> of {{PAGENAME}} in the drug label. | ||
|postmarketing=* Visual defects with vigabatrin administration | |||
* [[Flushing]], [[euphoria]], [[anxiety]] | |||
|postmarketing=Visual defects with vigabatrin administration | * Increased [[blood pressure]] and [[heart rate]] | ||
|drugInteractions= | |||
|drugInteractions= | |||
<!--Use in Specific Populations--> | <!--Use in Specific Populations--> | ||
|useInPregnancyFDA=* '''Pregnancy Category''' | |useInPregnancyFDA=* '''Pregnancy Category''' | ||
| Line 65: | Line 55: | ||
<!--Administration and Monitoring--> | <!--Administration and Monitoring--> | ||
|administration=* Oral | |administration=* [[Oral]] | ||
|monitoring=There is limited information regarding <i>Monitoring</i> of {{PAGENAME}} in the drug label. | |||
<!--IV Compatibility--> | <!--IV Compatibility--> | ||
| Line 76: | Line 64: | ||
<!--Overdosage--> | <!--Overdosage--> | ||
|overdose= | |overdose= | ||
There is limited information regarding <i>Chronic Overdose</i> of {{PAGENAME}} in the drug label. | There is limited information regarding <i>Chronic Overdose</i> of {{PAGENAME}} in the drug label. | ||
| Line 94: | Line 71: | ||
<!--Drug box 2--> | <!--Drug box 2--> | ||
|drugBox=<!--Mechanism of Action--> | |drugBox=<!--Mechanism of Action--> | ||
|mechAction= | |mechAction= | ||
<!--Structure--> | <!--Structure--> | ||
| Line 114: | Line 91: | ||
<!--How Supplied--> | <!--How Supplied--> | ||
|packLabel=<!--Patient Counseling Information--> | |packLabel=<!--Patient Counseling Information--> | ||
|fdaPatientInfo=There is limited information regarding <i>Patient Counseling Information</i> of {{PAGENAME}} in the drug label. | |fdaPatientInfo=There is limited information regarding <i>Patient Counseling Information</i> of {{PAGENAME}} in the drug label. | ||
Revision as of 20:26, 3 April 2015
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ammu Susheela, M.D. [2]
Disclaimer
WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.
Overview
Gamma-aminobutyric acid is an anxiolytic that is FDA approved for the treatment of epilepsy. Common adverse reactions include hypersensitivity.
Adult Indications and Dosage
FDA-Labeled Indications and Dosage (Adult)
- Adults and children 5 to 10 drops orally, 1 time daily or as otherwise directed by a health care professional. If symptoms persist, consult your health care professional. * Consult a physician for use in children under 12 years of age.
Off-Label Use and Dosage (Adult)
Guideline-Supported Use
There is limited information regarding Off-Label Guideline-Supported Use of Gamma-aminobutyric acid in adult patients.
Non–Guideline-Supported Use
Pediatric Indications and Dosage
FDA-Labeled Indications and Dosage (Pediatric)
There is limited information regarding FDA-Labeled Use of Gamma-aminobutyric acid in pediatric patients.
Off-Label Use and Dosage (Pediatric)
Guideline-Supported Use
There is limited information regarding Off-Label Guideline-Supported Use of Gamma-aminobutyric acid in pediatric patients.
Non–Guideline-Supported Use
There is limited information regarding Off-Label Non–Guideline-Supported Use of Gamma-aminobutyric acid in pediatric patients.
Contraindications
Warnings
- WARNINGS: If pregnant or breast-feeding, ask a health professional before use.
Adverse Reactions
Clinical Trials Experience
There is limited information regarding Clinical Trial Experience of Gamma-aminobutyric acid in the drug label.
Postmarketing Experience
- Visual defects with vigabatrin administration
- Flushing, euphoria, anxiety
- Increased blood pressure and heart rate
Drug Interactions
There is limited information regarding Gamma-aminobutyric acid Drug Interactions in the drug label.
Use in Specific Populations
Pregnancy
- Pregnancy Category
- Australian Drug Evaluation Committee (ADEC) Pregnancy Category
There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Gamma-aminobutyric acid in women who are pregnant.
Labor and Delivery
There is no FDA guidance on use of Gamma-aminobutyric acid during labor and delivery.
Nursing Mothers
There is no FDA guidance on the use of Gamma-aminobutyric acid with respect to nursing mothers.
Pediatric Use
There is no FDA guidance on the use of Gamma-aminobutyric acid with respect to pediatric patients.
Geriatic Use
There is no FDA guidance on the use of Gamma-aminobutyric acid with respect to geriatric patients.
Gender
There is no FDA guidance on the use of Gamma-aminobutyric acid with respect to specific gender populations.
Race
There is no FDA guidance on the use of Gamma-aminobutyric acid with respect to specific racial populations.
Renal Impairment
There is no FDA guidance on the use of Gamma-aminobutyric acid in patients with renal impairment.
Hepatic Impairment
There is no FDA guidance on the use of Gamma-aminobutyric acid in patients with hepatic impairment.
Females of Reproductive Potential and Males
There is no FDA guidance on the use of Gamma-aminobutyric acid in women of reproductive potentials and males.
Immunocompromised Patients
There is no FDA guidance one the use of Gamma-aminobutyric acid in patients who are immunocompromised.
Administration and Monitoring
Administration
Monitoring
There is limited information regarding Monitoring of Gamma-aminobutyric acid in the drug label.
IV Compatibility
There is limited information regarding IV Compatibility of Gamma-aminobutyric acid in the drug label.
Overdosage
There is limited information regarding Chronic Overdose of Gamma-aminobutyric acid in the drug label.
Pharmacology
There is limited information regarding Gamma-aminobutyric acid Pharmacology in the drug label.
Mechanism of Action
There is limited information regarding Gamma-aminobutyric acid Mechanism of Action in the drug label.
Structure
File:Gamma-aminobutyric acid01.png This image is provided by the National Library of Medicine.
Pharmacodynamics
There is limited information regarding Pharmacodynamics of Gamma-aminobutyric acid in the drug label.
Pharmacokinetics
There is limited information regarding Pharmacokinetics of Gamma-aminobutyric acid in the drug label.
Nonclinical Toxicology
There is limited information regarding Nonclinical Toxicology of Gamma-aminobutyric acid in the drug label.
Clinical Studies
There is limited information regarding Clinical Studies of Gamma-aminobutyric acid in the drug label.
How Supplied
There is limited information regarding Gamma-aminobutyric acid How Supplied in the drug label.
Storage
There is limited information regarding Gamma-aminobutyric acid Storage in the drug label.
Images
Drug Images
{{#ask: Page Name::Gamma-aminobutyric acid |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}
Package and Label Display Panel
{{#ask: Label Page::Gamma-aminobutyric acid |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}
Patient Counseling Information
There is limited information regarding Patient Counseling Information of Gamma-aminobutyric acid in the drug label.
Precautions with Alcohol
- Alcohol-Gamma-aminobutyric acid interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.
Brand Names
- GABA PHENOLIC ®[1]
Look-Alike Drug Names
There is limited information regarding Gamma-aminobutyric acid Look-Alike Drug Names in the drug label.
Drug Shortage Status
Price
References
The contents of this FDA label are provided by the National Library of Medicine.
{{#subobject:
|Label Page=Gamma-aminobutyric acid |Label Name=GABA 01.jpg
}}
{{#subobject:
|Label Page=Gamma-aminobutyric acid |Label Name=DailyMed - GABA PHENOLIC - .gamma.-aminobutyric acid liquid .png
}}
}}